Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
8/15/22 | Novartis (NVS) | Ilaris for Non-Small Cell Lung Cancer (NSCLC) | Subscribers Only | Subscribers Only | Subscribers Only |
8/11/22 | NewAmsterdam | Obicetrapib for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
8/10/22 | Bristol Myers Squibb (BMY) | Abecma for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
8/9/22 | Verona Pharma (VRNA) | RPL554 (Inhaled) for Chronic Obstructive Pulmonary Disease (COPD) | Subscribers Only | Subscribers Only | Subscribers Only |
8/9/22 | Formosa Pharmaceuticals | APP13007 for Ocular Pain and/or Inflammation (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
08/13/22 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (US) |
08/13/22 | Subscribers Only | Subscribers Only | Regulatory - PDUFA/Approval Decision (US) |
08/15/22 | Subscribers Only | Subscribers Only | Regulatory - Meeting with FDA |
08/17/22 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |
08/17/22 | Subscribers Only | Subscribers Only | Partnership - Acquisition Completion |